Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 1
R&D Momentum
65/100
Pipeline Velocity
19/100
Trial Completion Rate
94/100
Pipeline Concentration
50/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
Genomic Sequencing for Evaluation of Uncommon Disease Manifestations Through the Childhood Complex Disease Genomic Section
Genome Medical Sequencing for Gene Discovery
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients
Deciphering the Genetic Architecture of Autoimmune Diseases
Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Genetics of Type 2 Diabetes in Diverse Populations
Incidental Detection of Maternal Neoplasia Through Non-invasive Cell-Free DNA Analysis (IDENTIFY), a Natural History Study
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Development of the Family Map: Examination of Communal Coping Across Disease Context
Diagnosis and Treatment of Patients With Inborn Errors of Metabolism or Other Genetic Disorders
Studies of Genetic Heterogeneity in Patients With Lysosomal Storage Disorders
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)